Enodia Therapeutics has raised €20.7m ($25m) in seed funding to advance a small-molecule platform for targeted protein degradation using proteomics and machine learning (ML).
This investment was co-led by Bpifrance, Elaia, and Pfizer Ventures, with participation from Argobio Studio, InvestSud, MACSF, Mission BioCapital, Sambrinvest, The Institut Pasteur, and Wallonie Entreprendre.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company’s discovery platform is based on science developed at The Institut Pasteur and incorporates ML to selectively modulate the secretory pathway translocon 61 (SEC61) translocon.
The translocon is responsible for directing secreted and transmembrane proteins into the secretory pathway during synthesis.
By intervening at this stage, Enodia aims to address disease mechanisms upstream without affecting essential physiological functions or causing damage.
Enodia employs a combination of a large chemical space covering various families of inhibitors and a purpose-built library of signal-peptide cell lines. The approach integrates structural validation, machine learning-driven selectivity, and proteomics-based secretome analysis to guide rational drug design.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEnodia Therapeutics CEO Yves Ribeill said: “We are grateful for the strong support and confidence from our investors, which reflects their conviction in our scientific approach and team.
“This financing supports the advancement of our small-molecule approach to modulating the SEC61 translocon, with machine learning enabling greater selectivity in targeted protein degradation than previous approaches.
“Over the next year, we plan to progress our lead programme toward preclinical candidate selection, thereby establishing a key value inflection point and the foundation for subsequent IND-enabling development.”
Argobio Studio and The Institut Pasteur created Enodia Therapeutics. Early validation for its platform and translational activities received further support from the Mission BioCapital Platinum Program.
